The Special Committee Of The Board Of Directors Of Liminal Biosciences Retains An Independent Financial Advisor In Response To Unsolicited Non-Binding Transaction Proposal

 Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), re-confirms that the board of directors of the Company has already established a special committee of the independent members of the Company's board of directors (the "Special Committee") in respect to the previously announced unsolicited non-binding proposal from Structured Alpha LP ("SALP") to acquire all of the issued and outstanding common shares of the Company that SALP does not currently own for US$7.50 in cash per common share (the "Proposal").  The Special Committee has retained BMO Capital Markets as its independent financial advisor and to provide a formal valuation of the common shares of the Company in accordance with Multilateral Instrument 61-101 – Protection of Minority Shareholders in Special Transactions.

The Special Committee will evaluate the Proposal and all viable alternatives that may be available to the Company. No decisions or recommendations have been made by the Special Committee regarding the transactions that are the subject of the Proposal at this time. Shareholders do not need to take any action with respect to the Proposal at this time.

Notwithstanding the process described above, there can be no assurance that the Proposal will result in a formal offer or that any such offer will ultimately result in a completed transaction. The Company intends to provide updates if and when necessary, in accordance with applicable securities laws.